Cellipont completes cell therapy Texas plant

Announced in August 2022, the facility will include seven clean rooms, quality check (QC) labs, a temperature-controlled storage, segregated shipping bays, a warehouse, and administrative offices. The facility will focus on cell therapy advancement.

According to the contract development and manufacturing organization (CDMO), the expansion is a significant milestone for Cellipont in the development and production of cell therapies for its customers globally.

“Equipped with the latest technology and designed to meet the highest quality standards, this facility represents our dedication to advancing cell therapy manufacturing and, most importantly, to serving the patients in need,” said Darren Head, executive chairman of the Board for Cellipont.

“We’re thrilled to see this investment come to fruition and contribute to the advancement of life-saving therapies worldwide.”

This is the second expansion that the San Diego-based firm has completed to support cell therapy development and production capabilities. The firm expanded its Poway facility in California in 2022.

As confirmed by the company’s CEO Deborah Wild, The Woodlands facility will support technological transfers and meet the customers’ needs. Additionally, the site will be Cellipont’s headquarters as well as its flagship for commercial manufacturing.

“As Cellipont commenced the design phase for The Woodlands facility in early 2022, we made a strategic decision: to not only meet current regulatory standards but also anticipate future ones. In the continually evolving landscape of cell therapy, we, as a leading CDMO, aimed to stay ahead of the curve,” said Michael O'Mara, chief operating officer for Cellipont.

The cell therapy CDMO that sprung out from the acquisition of Performance Cell Manufacturing by private equity firm Great Point Partners, launched in 2022. The transaction closed with an undisclosed fee.

Cellipont did not respond when contacted by this publication. The financials of this expansion have not been disclosed.